Clinical Trial Update: A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update showing MET233 in combination with MET097 for obesity or overweight conditions, with or without diabetes, is in Phase 1/Phase 2 and curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Obesity

Drugs mentioned

• MET097
• MET233

Snippet

Sponsor: Metsera, a wholly owned subsidiary of Pfizer | Conditions: Obesity and Obesity-related Medical Conditions | Phase 1, Phase 2 | Status: RECRUITING